A case of Parkinsonism worsened by losartan: A probable new adverse effect

Movement Disorders

Volumn 23, Issue 7, 2008, Pages 1055-

  Sarma, G R K ^a   Kamath, Vikram ^a   Matthew, Thomas ^a   Roy, A K ^a  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; LOSARTAN; RAMIPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AGED; BLOOD PRESSURE REGULATION; BRADYKINESIA; CASE REPORT; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALLING; GAIT DISORDER; HAND TREMOR; HUMAN; HYPERTENSION; LETTER; MALE; PARKINSONISM; PRIORITY JOURNAL; RETREATMENT; RIGIDITY; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; WALKING DIFFICULTY; DRUG INTERACTION; HOSPITALIZATION; PARKINSON DISEASE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DOPAMINE AGONISTS; DRUG INTERACTIONS; HUMANS; HYPERTENSION; LEVODOPA; LOSARTAN; MALE; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 49249097247     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21945     Document Type: Letter

References (4)

1. Allen AM, Paxinos G, McKinley MJ, Chai SY, Mendelsohn FA. Localization and characterization of angiotensin II receptor binding sites in the human basal ganglia, thalamus, midbrain pons, and cerebellum. J Comp Neurol 1991;312:291-298.
2. Allen AM, MacGregor DP, Chai SY, et al. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 1992;32:339-344.
3. Brown DC, Steward LJ, Ge J, Barnes NM. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 1996;118:414-420.
4. Reardon KA, Mendelsohn FA, Chai SY, Home MK. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust N Z J Med 2000;30:48-53.